Peak Bio, Inc. Awarded Patent With Broad Coverage for Thailanstatin-ADC Platform Technology (PH-1) a Payload With Novel Immunomodulatory Effects That Target RNA Splicing
Peak Bio, Inc. Awarded Patent With Broad Coverage for Thailanstatin-ADC Platform Technology (PH-1) a Payload With Novel Immunomodulatory Effects That Target RNA Splicing
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled "Thailanstatin Analogs" by The United States Patent and Trademark Office (USPTO). The new patent describes properties of potent heteroaryl-substituted Thailanstatin payloads, proprietary non-cleavable and cleavable linkers, and antibody-drug conjugate (ADC) technology derived from it. Peak Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer.
加利福尼亞州普萊森頓，2024年1月4日（GLOBE NEWSWIRE）——匹克生物有限公司（“Peak Bio” 或 “公司”）（OTCQB）PK：PKBO）宣佈，它被美國專利商標局（USPTO）授予了名爲 “泰國他汀類似物” 的第11,691,982 B2號美國專利。新專利描述了強效的雜芳基取代泰國他汀有效載荷、專有的不可裂解和可分解的連接劑以及由其衍生的抗體藥物偶聯物（ADC）技術的特性。Peak Bio是一家臨床階段的生物製藥公司，專注於開發和商業化下一代創新療法，旨在改善和解決炎症、罕見特種疾病和癌症患者未得到滿足的重大醫療需求。
The patent granted by the USPTO covers claims for the Company's potent Thailanstatin payload platform specific to the spliceosome protein, SF3B1. This patent application is a divisional patent of the Company's R&D toxin portfolio on Thailanstatin, termed PH-1, building on the portfolio of previously issued patents (Patent No. US 10,815,246 B2, and Patent No. US 10,301,319 B2). Grant Patent right for PCT/US2018/051721 family was issued by China National Intellectual Property Administration in Aug 2023, and in Israel in Sept 2023. Corresponding foreign patent applications are pending and currently undergoing examination in PCT countries - Australia, Canada, the European Patent Office, Japan, Mexico, New Zealand, Singapore, and others.
美國專利商標局授予的專利涵蓋了對該公司針對剪接體蛋白 SF3B1 的強效泰國他汀有效載荷平台的索賠。該專利申請是該公司在泰國他汀上的研發毒素產品組合（名爲PH-1）的分部專利，該專利建立在先前頒發的專利組合（專利號美國 10,815,246 B2，專利號我們 10,301,319 (B2)。PCT/US2018/051721系列的授予專利權由中國國家知識產權局於2023年8月頒發，以色列於2023年9月頒發。相應的外國專利申請正在等待中，目前正在PCT國家——澳大利亞、加拿大、歐洲專利局、日本、墨西哥、新西蘭、新加坡和其他國家——進行審查。
Structure-activity-relationship studies for novel compounds and medicinal chemistry routes for their synthesis are also described. This Patent is an important addition to the intellectual property portfolio surrounding the Company's ADC technology, and significantly enhances the patent position for both internal and future potential partner programs.
還描述了新化合物的結構-活性-關係研究及其合成的藥物化學途徑。該專利是圍繞公司ADC技術的知識產權組合的重要補充，極大地提高了內部和未來潛在合作伙伴計劃的專利地位。
Peak Bio is developing a differentiated Trop2 PH1 ADC and is investigating collaborations for clinical development and/ or commercialization of this asset along with other collaboration opportunities that incorporate our novel payloads.
Peak Bio正在開發一種差異化的Trop2 PH1 ADC，並正在研究該資產的臨床開發和/或商業化的合作，以及納入我們新有效載荷的其他合作機會。
Stephen LaMond, PharmD, MBA, Peak Bio, Inc. Interim CEO and COO, commented, "We are pleased to announce the grant of our patents in US, China and Israel and the continued progress with our oncology portfolio (ADCs) that incorporate our novel payloads. We believe the strong interest in novel payloads and ADCs in general will continue given the need for novel and differentiated approaches to the treatment of cancers now and in the future."
Peak Bio, Inc.臨時首席執行官兼首席運營官藥學博士、工商管理碩士Stephen LaMond評論說：“我們很高興地宣佈，我們在美國、中國和以色列獲得了專利，並且我們的腫瘤學產品組合（ADC）在納入我們的新型有效載荷方面繼續取得進展。我們相信，鑑於現在和將來都需要新的差異化癌症治療方法，人們對新型有效載荷和ADC的濃厚興趣將繼續下去。”
Several of the Company's management team will participate in the various events and activities surrounding the J.P. Morgan 41st Annual Healthcare Conference 2024. The annual J.P. Morgan Healthcare Conference is the largest and most informative event for the global pharmaceutical industry and the investment community. This year, the conference will take place in San Francisco, CA, the United States, on January 8-11. The management team will be available for meetings during this week. Please contact Stephen LaMond, Interim CEO @steve.lamond@peak-bio.com to schedule any meetings.
公司的幾位管理團隊將參加與摩根大通2024年第41屆年度醫療保健會議相關的各種活動和活動。一年一度的摩根大通醫療保健會議是全球製藥行業和投資界規模最大、內容最豐富的活動。今年，會議將於1月8日至11日在美國加利福尼亞州舊金山舉行。管理團隊將在本週參加會議。請聯繫臨時首席執行官斯蒂芬·拉蒙德 @ steve.lamond@peak-bio.com 安排任何會議。
About Peak Bio, Inc.
關於 Peak Bio, Inc.
Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases.
Peak Bio, Inc. 是一家處於臨床階段的生物製藥公司，專注於開發用於治療腫瘤學和炎症性孤兒病/罕見病的下一代療法。
Peak Bio's lead product candidate, PHP-303, is a 5th generation, small molecule, neutrophil elastase inhibitor currently awaiting initiation of a Phase II clinical study in the genetic orphan disease called Alpha1 anti-trypsin deficiency disorder (AATD). Peak Bio has successfully completed two Phase 1 clinical studies in human subjects: a single ascending dose trial (SAD) and a multiple ascending dose trial (MAD). The SAD and MAD PHP-303 clinical studies demonstrated a favorable safety profile, and a dose was established for Peak Bio's upcoming clinical trials.
Peak Bio的主要候選產品 PHP-303 是第五代小分子中性粒細胞彈性蛋白酶抑制劑，目前正在等待啓動一項名爲Alpha1抗胰蛋白酶缺乏症（AATD）的遺傳性孤兒病的II期臨床研究。Peak Bio已成功完成兩項針對人類受試者的1期臨床研究：單劑量上升試驗（SAD）和多劑量遞增試驗（MAD）。SAD 和 MAD PHP-303 臨床研究顯示出良好的安全性，Peak Bio 即將進行的臨床試驗已經確定了劑量。
Peak Bio's cancer platform consists of novel payloads/toxins in conjunction with an antibody-drug conjugate (ADC) platform that seeks to address a growing unmet need in cancer care. Peak Bio's current ADC approach has a dual mechanism of action that seeks to unite conventional and direct targeting of cancer cells with toxins while also engaging the immune system with the added potential to enhance cancer cell killing. The Peak Bio payload seeks to stimulate the immune system by leaving behind immune memory cells that continue to kill cancer cells following the initial therapeutic intervention even in the absence of further ADC treatments. The potential for immune reengagement when the cancer reoccurs could be an exciting and important advancement in cancer care with this dual mechanistic approach to cancer therapeutics. Peak Bio's lead payload appears to be a poor substrate for multi-drug resistance (MDR) transporters which is a growing concern in the ADC field.
Peak Bio的癌症平台由新的有效載荷/毒素以及抗體藥物偶聯物（ADC）平台組成，該平台旨在滿足不斷增長的癌症護理需求。Peak Bio目前的ADC方法具有雙重作用機制，旨在將癌細胞的傳統和直接靶向與毒素結合起來，同時還通過增強癌細胞殺傷的額外潛力來吸引免疫系統。Peak Bio有效載荷旨在通過留下免疫記憶細胞來刺激免疫系統，即使沒有進一步的ADC治療，這些免疫記憶細胞在最初的治療干預後仍能殺死癌細胞。採用這種雙重機制的癌症治療方法，癌症復發時免疫重新參與的潛力可能是癌症治療領域一項激動人心的重要進展。Peak Bio的鉛有效載荷似乎是多耐藥（MDR）轉運蛋白的不良底物，這在ADC領域越來越受到關注。
譯文內容由第三人軟體翻譯。